Victoria M Chia

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. doi request reprint Prevalence and incidence of comorbidities in elderly women with ovarian cancer
    Victoria M Chia
    Amgen Inc, Thousand Oaks, CA, USA
    Gynecol Oncol 129:346-52. 2013
  2. doi request reprint Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy
    Victoria M Chia
    Center for Observational Research, Amgen Inc, Thousand Oaks, CA, USA
    Breast Cancer Res Treat 138:621-31. 2013
  3. doi request reprint History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis
    Chun Chao
    Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
    Leuk Lymphoma 56:72-9. 2015
  4. doi request reprint Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy
    Mi Rim Choi
    Amgen Inc, One Amgen Center Drive, M S 17 1 A, Thousand Oaks, CA, 91320, USA
    Support Care Cancer 22:1619-28. 2014
  5. doi request reprint Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma
    Wendy J Langeberg
    Amgen, Inc, Thousand Oaks, CA, USA
    Support Care Cancer 22:2167-75. 2014

Collaborators

Detail Information

Publications5

  1. doi request reprint Prevalence and incidence of comorbidities in elderly women with ovarian cancer
    Victoria M Chia
    Amgen Inc, Thousand Oaks, CA, USA
    Gynecol Oncol 129:346-52. 2013
    ..Studies suggest comorbidity plays an important role in ovarian cancer. We characterized the epidemiology of comorbid conditions in elderly U.S. women with ovarian cancer...
  2. doi request reprint Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy
    Victoria M Chia
    Center for Observational Research, Amgen Inc, Thousand Oaks, CA, USA
    Breast Cancer Res Treat 138:621-31. 2013
    ..This information, if confirmed by others, may aid clinical decision making with respect to use of prophylactic G-CSF during chemotherapy treatment...
  3. doi request reprint History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis
    Chun Chao
    Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
    Leuk Lymphoma 56:72-9. 2015
    ..2-2.2]), HIV infection (HR = 3.8 [2.0-6.7]) and rheumatoid diseases (HR = 2.4 [1.3-4.0]) were associated with significantly increased risk of FN. These results provide evidence that chronic comorbidity increases the risk of FN...
  4. doi request reprint Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy
    Mi Rim Choi
    Amgen Inc, One Amgen Center Drive, M S 17 1 A, Thousand Oaks, CA, 91320, USA
    Support Care Cancer 22:1619-28. 2014
    ..We performed a retrospective analysis using a subset of the Medicare 5 % database to assess patterns of G-CSF use and FN occurrence among elderly cancer patients receiving myelosuppressive chemotherapy...
  5. doi request reprint Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma
    Wendy J Langeberg
    Amgen, Inc, Thousand Oaks, CA, USA
    Support Care Cancer 22:2167-75. 2014
    ....